Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

120.28 +1.16 (+0.97%)
Streaming Delayed Price Updated: 11:51 AM EDT, Apr 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
51 52 Next >
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen. 
Via Investor's Business Daily
Biogen Names Christopher Viehbacher President and Chief Executive Officer
Distinguished Industry Leader Brings Extensive International Experience in Large Pharmaceutical and Entrepreneurial Biotech Companies 
From Biogen Inc.
Via GlobeNewswire
Elliott Wave Technical Analysis: Biogen Inc. - Thursday, Nov. 10
Looking for a clear three-wave move pullback before considering any long-term longs. 
Via Talk Markets
The Power of McKinsey
Author Michael Forsythe talks about his new book, "When McKinsey Comes to Town: The Hidden Influence of the World's Most Powerful Consulting Firm." 
Via The Motley Fool
Is Biogen Poised for a Bull Run?
Biogen has been a market-beating stock this year, but can that trend continue? 
Via The Motley Fool
Biogen (BIIB) Q3 2022 Earnings Call Transcript
BIIB earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Biogen Raises Annual Guidance Despite Q3 Earning Impacted By Biosimilar Competition
Via Benzinga
Biogen To Rally Around 15%? Here Are 5 Other Price Target Changes For Tuesday
Mizuho raised Biogen Inc. (NASDAQ: BIIB) price target from $270 to $325. Mizuho analyst Salim Syed maintained the stock with a Buy rating. Biogen shares fell 0.3% to close at $283.44 on Monday. 
Via Benzinga
Don't Get Used to Lower Medicare Part B Premiums -- Here's Why
Medicare might have to begin paying billions of extra dollars for new drugs in the not-too-distant future. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Stock Market Rally Resilient As Apple Bucks Megacap Meltdown: Weekly Review
The Dow and S&P 500 moved above a key level while the Nasdaq rose. 
Via Investor's Business Daily
Earnings Scheduled For October 25, 2022
Companies Reporting Before The Bell • UBS Gr (NYSE:UBS) is expected to report earnings for its third quarter. • SAP (NYSE:SAP) is expected to report earnings for its third quarter. 
Via Benzinga
15 Analysts Have This to Say About Biogen
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter: 
Via Benzinga
Is Biogen Stock a Buy Now That Guidance Has Been Raised?
Biogen stock (NASDAQ:BIIB) continues to get excellent news. On Tuesday, the pharmaceutical company released its third-quarter results, and for the first time in a long time, investors found something... 
Via PressReach
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
Upgrades 
Via Benzinga
Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
From Biogen Inc.
Via GlobeNewswire
Biogen To Report Q3 Earnings: Here's What To Expect
Biogen will report third-quarter 2022 results on Oct 25, before market open. 
Via Talk Markets
New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS
From Biogen Inc.
Via GlobeNewswire
Is Biogen a Buy After It Boosted Guidance?
There's a much bigger story for this biotech than its improved 2022 outlook. 
Via The Motley Fool
Biogen Inc. Surpasses Q3 Earnings And Revenue Estimates
Biogen Inc. came out with quarterly earnings of $4.77 per share. 
Via Talk Markets
Biogen Inches Higher On Third-Quarter Beat, But All Eyes Watch Alzheimer's Drug
Biogen's partner, Eisai, will present Phase 3 results for lecanemab next month. 
Via Investor's Business Daily
Recap: Biogen Q3 Earnings
Biogen (NASDAQ:BIIB) reported its Q3 earnings results on Tuesday, October 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Biogen beat estimated earnings by... 
Via Benzinga
Where Biogen Stands With Analysts
Over the past 3 months, 15 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Biogen Q3 Earnings Preview: Key Items For Investors To Watch
Biogen Inc (NASDAQ: BIIB) is scheduled to report its third-quarter earnings on Tuesday during the premarket session amid cautious hope for its neurodegenerative disease programs and an ongoing 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $400 Today
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.47% on an annualized basis producing an average annual return of 9.66%. Currently, Biogen has a market capitalization of... 
Via Benzinga
Earnings Preview: Biogen
Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Tuesday, 2022-10-25. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report an... 
Via Benzinga
3 Alzheimer's Therapy Stocks to Invest in
Alzheimer's treatments could make a big winner of these stocks. 
Via The Motley Fool
This Beaten-Down ETF Is Still a Screaming Bear-Market Buy
Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund. 
Via The Motley Fool
Biogen Whale Trades For October 20
A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 12 strange trades. 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback